Taking advantage of its growing availability, Ong et al. performed a small retrospective cohort study of 20 men to demonstrate the utility of PSMA-PET/CT in the identification of patients with true oligometastatic prostate cancer who would stand to gain the largest therapeutic benefit from SABR. This evidence concerns the gene FOLH1 and Familial prostate cancer.